FDA expands use of rivaroxaban to treat, reduce recurrence of DVT, PE

Article

FDA has expanded the approved use of oral anticoagulant rivaroxaban (Xarelto, Janssen) to include three new indications: treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and reducing the risk of recurrent DVT and PE following initial treatment.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.